Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and metaanalysis
作者机构：Internal MedicineCreighton University School of MedicinePhoenixAZ 85013United States CardiologyHeart CenterUniversity of Arizona College of Medicine-PhoenixBanner University Medical CenterPhoenixAZ 85006United States Department of Family MedicineMayo ClinicScottsdaleAZ 85260United States
出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)
年 卷 期：2022年第14卷第11期
页 面：599-616页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Metabolic syndrome Sodium-glucose cotransporter 2 inhibitors Dapagliflozin Empagliflozin Cardiovascular disease
摘 要：BACKGROUND Landmark trials have established the benefits of sodium-glucose cotransporter-2 inhibitors(SGLT2-Is)in cardiovascular disease including heart failure with reduced and preserved ejection fraction and renal diseases regardless of the presence of diabetes ***,studies evaluating the role of SGLT2-Is in metabolic syndrome(MetS)are *** This study primarily aimed to evaluate the impact of SGLT2-Is on the components of *** Two independent reviewers and an experienced librarian searched Medline,Scopus and the Cochrane central from inception to December 9,2021 to identify placebo controlled randomized controlled trials that evaluated the impact of SGLT2-Is on the components of MetS as an ***-and post-treatment data of each component were obtained.A meta-analysis was performed using the RevMan(version 5.3;Copenhagen:The Nordic Cochrane Center,The Cochrane Collaboration).RESULTS Treatment with SGLT2-Is resulted in a decrease in fasting plasma glucose(–18.07 mg/dL;95%CI:-25.32 to–10.82),systolic blood pressure(–1.37 mmHg;95%CI:-2.08 to–0.65),and waist circumference(–1.28 cm;95%CI:-1.39 to–1.18)compared to *** impact on highdensity lipoprotein cholesterol was similar to placebo(0.01 mg/dL;95%CI:-0.05 to 0.07).CONCLUSION SGLT2-Is have a promising role in the management of MetS.
维普期刊数据库